statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	405
GB - Regno Unito	130
CN - Cina	101
SG - Singapore	88
IT - Italia	70
IE - Irlanda	69
SE - Svezia	69
RU - Federazione Russa	54
DE - Germania	46
HK - Hong Kong	36
VN - Vietnam	36
UA - Ucraina	29
TR - Turchia	27
EU - Europa	23
FR - Francia	23
IN - India	21
KR - Corea	21
BR - Brasile	17
BD - Bangladesh	16
NL - Olanda	13
CO - Colombia	10
FI - Finlandia	10
JP - Giappone	10
BE - Belgio	6
MX - Messico	5
ID - Indonesia	4
AR - Argentina	3
CA - Canada	3
PK - Pakistan	3
CL - Cile	2
IQ - Iraq	2
TN - Tunisia	2
ZA - Sudafrica	2
AM - Armenia	1
AT - Austria	1
CH - Svizzera	1
CI - Costa d'Avorio	1
DJ - Gibuti	1
EC - Ecuador	1
EG - Egitto	1
HU - Ungheria	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
NP - Nepal	1
PA - Panama	1
PH - Filippine	1
PT - Portogallo	1
SI - Slovenia	1
SK - Slovacchia (Repubblica Slovacca)	1
VE - Venezuela	1
Totale	1.374

Nome	#
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer : a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)	204
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy : a retrospective study	158
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy	151
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases : impact on patient management	143
Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles.	137
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy	135
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer	134
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial)	131
Biomarker expression and survival after primary chemotherapy for breast cancer	130
Exact method for analysis after single-stage and two-stage phase II cancer clinical trial	127
Totale	1.450

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	55	2	2	5	1	1	1	10	2	2	5	0	24
2022/2023	109	10	2	4	26	18	22	0	4	9	7	4	3
2023/2024	67	4	9	3	2	11	0	4	4	1	2	17	10
2024/2025	129	11	10	0	7	6	3	1	36	6	8	14	27
2025/2026	380	20	18	32	21	30	22	51	35	43	73	15	20
2026/2027	25	25	0	0	0	0	0	0	0	0	0	0	0
Totale													1.450

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca